ZEVRA THERAPEUTICS, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Zevra reported Q3 2026 net revenue of $37.8M (vs. $26.1M in Q3 2025), with $34.0M from MIPLYFFA (arimoclomol for Niemann-Pick disease type C). 197 total U.S. prescriptions enrolled since launch; 134 patients in global Expanded Access Program. Cash position of $270.9M as of September 30, 2026. Net income of $19.2M for Q3 2026 vs. net loss of $0.5M in Q3 2025. Pipeline: celiprolol Phase 3 trial (72 enrolled, 4 events); sNDA filing anticipated Q1 2027 for pediatric indication.
Why this rating
Strong commercial traction and cash burn profile support near-term runway, but absolute revenue ($37.8M quarterly) is moderate relative to $455M market cap; typical biotech growth phase execution.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.